Publications by authors named "Lonnie D Brent"
Article Synopsis
- - Infusion-related reactions (IRRs) are common with therapies like chemotherapy and immunotherapy, and diphenhydramine has been the primary IV antihistamine used for over 60 years despite lacking FDA approval for this purpose.
- - In 2019, IV cetirizine was approved and offered a safer alternative with fewer side effects compared to diphenhydramine, proving equally effective in managing IRRs while potentially reducing treatment time and visits.
- - The FDA has required many infusion products to include premedication guidelines, suggesting that IV cetirizine should be actively considered for preventing and managing IRRs in clinical settings.
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel.
View Article and Find Full Text PDF